In a large clinical trial of adjuvant therapy (treatment after surgery) for early-stage pancreatic cancer, researchers evaluated whether treatment with gemcitabine (Gemzar) helped patients live longer.
The first phase III clinical trial to test adjuvant chemotherapy (chemotherapy after surgery) with gemcitabine (Gemzar) for people with operable pancreatic cancer (cancer that can be surgically removed) shows that this treatment nearly doubles the amount of time it takes for the cancer to return.
